These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36623777)

  • 21. Risk stratification of patients with nonalcoholic fatty liver disease using a case identification pathway in primary care: a cross-sectional study.
    Shaheen AA; Riazi K; Medellin A; Bhayana D; Kaplan GG; Jiang J; Park R; Schaufert W; Burak KW; Sargious M; Swain MG
    CMAJ Open; 2020; 8(2):E370-E376. PubMed ID: 32414883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in Prevalence of Nonalcoholic Fatty Liver Disease in US Adults with Prediabetes.
    Le P; Chaitoff A; Rothberg MB; Alkhouri N; McCullough A
    J Gen Intern Med; 2019 Nov; 34(11):2336-2338. PubMed ID: 31325127
    [No Abstract]   [Full Text] [Related]  

  • 23. How to Approach a Patient With Nonalcoholic Fatty Liver Disease.
    Tilg H
    Gastroenterology; 2017 Aug; 153(2):345-349. PubMed ID: 28647352
    [No Abstract]   [Full Text] [Related]  

  • 24. Preparing for the NASH Epidemic: A Call to Action.
    Kanwal F; Shubrook JH; Younossi Z; Natarajan Y; Bugianesi E; Rinella ME; Harrison SA; Mantzoros C; Pfotenhauer K; Klein S; Eckel RH; Kruger D; El-Serag H; Cusi K
    Gastroenterology; 2021 Sep; 161(3):1030-1042.e8. PubMed ID: 34416976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease.
    Sanyal AJ; Mathurin P; Nagy LA
    Gastroenterology; 2016 Jun; 150(8):1695-7. PubMed ID: 27155520
    [No Abstract]   [Full Text] [Related]  

  • 27. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).
    Fan JG; Wei L; Zhuang H;
    J Dig Dis; 2019 Apr; 20(4):163-173. PubMed ID: 30444584
    [No Abstract]   [Full Text] [Related]  

  • 28. Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect.
    Heda R; Yazawa M; Shi M; Bhaskaran M; Aloor FZ; Thuluvath PJ; Satapathy SK
    World J Gastroenterol; 2021 May; 27(17):1864-1882. PubMed ID: 34007127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nonalcoholic Fatty Liver Disease: A Silent Epidemic.
    Sivell C
    Gastroenterol Nurs; 2019; 42(5):428-434. PubMed ID: 31574071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.
    Wong VW; Chan WK; Chitturi S; Chawla Y; Dan YY; Duseja A; Fan J; Goh KL; Hamaguchi M; Hashimoto E; Kim SU; Lesmana LA; Lin YC; Liu CJ; Ni YH; Sollano J; Wong SK; Wong GL; Chan HL; Farrell G
    J Gastroenterol Hepatol; 2018 Jan; 33(1):70-85. PubMed ID: 28670712
    [No Abstract]   [Full Text] [Related]  

  • 31. Preparing for the NASH epidemic: A call to action.
    Kanwal F; Shubrook JH; Younossi Z; Natarajan Y; Bugianesi E; Rinella ME; Harrison SA; Mantzoros C; Pfotenhauer K; Klein S; Eckel RH; Kruger D; El-Serag H; Cusi K
    Obesity (Silver Spring); 2021 Sep; 29(9):1401-1412. PubMed ID: 34365735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nonalcoholic fatty liver disease: a systematic review.
    Rinella ME
    JAMA; 2015 Jun; 313(22):2263-73. PubMed ID: 26057287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic Fatty Liver Disease.
    Sweet PH; Khoo T; Nguyen S
    Prim Care; 2017 Dec; 44(4):599-607. PubMed ID: 29132522
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical features of pediatric nonalcoholic fatty liver disease: a need for increased awareness and a consensus for screening.
    Middleton JP; Wiener RC; Barnes BH; Gurka MJ; DeBoer MD
    Clin Pediatr (Phila); 2014 Dec; 53(14):1318-25. PubMed ID: 24477713
    [No Abstract]   [Full Text] [Related]  

  • 35. Beyond a liver-gut focus: the evolution of gastroenterology and hepatology in challenging the obesity and steatotic liver disease paradigm.
    Brennan PN; Zelber-Sagi S; Allen AM; Dillon JF; Lazarus JV
    Gut; 2024 Mar; 73(4):560-563. PubMed ID: 37898546
    [No Abstract]   [Full Text] [Related]  

  • 36. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease.
    Cotter TG; Rinella M
    Gastroenterology; 2020 May; 158(7):1851-1864. PubMed ID: 32061595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Nonalcoholic fatty liver disease: What do we know and what will we have to learn?].
    Volkova NI; Porksheyan MI
    Ter Arkh; 2017; 89(2):91-98. PubMed ID: 28393828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonalcoholic Fatty Liver Disease.
    Filipović B; Forbes A; Tepeš B; Dumitraşcu DL
    Can J Gastroenterol Hepatol; 2018; 2018():2097435. PubMed ID: 30155450
    [No Abstract]   [Full Text] [Related]  

  • 39. Referral care paths for non-alcoholic fatty liver disease-Gearing up for an ever more prevalent and severe liver disease.
    van Dijk AM; Schattenberg JM; Holleboom AG; Tushuizen ME
    United European Gastroenterol J; 2021 Oct; 9(8):903-909. PubMed ID: 34609086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.
    Harrison SA; Gawrieh S; Roberts K; Lisanti CJ; Schwope RB; Cebe KM; Paradis V; Bedossa P; Aldridge Whitehead JM; Labourdette A; Miette V; Neubauer S; Fournier C; Paredes AH; Alkhouri N
    J Hepatol; 2021 Aug; 75(2):284-291. PubMed ID: 33746083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.